MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
BHVN - Biohaven Pharmaceutical Holding Company Ltd
$112.91
0.67(0.60%)7:26:38 PM 12/1/2021
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Related Peers

Stock news

    11/18/2021BHVN
    Notable Biohaven Pharma Hldgs Insider Trades $8.8M In Company Stock

    Declan Doogan, Insider at Biohaven Pharma Hldgs (NYSE:BHVN), made a large buy and sell of company shares on November 16, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Declan Doogan exercised options to purchase 559,000 Biohaven Pharma Hldgs shares at prices ranging from $0.61 to $61.76 per share for a total of $4,398,760 on November 16. They then sold their shares on the same day in the open market. They sold at prices

    11/18/2021BHVN
    Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease

    Biohaven to leverage Artizan’s biobanking expertise and proprietary drug discovery engine to create Parkinson’s disease drug development programNEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, and Biohaven Therapeutics Ltd. (“Biohaven”, parent company NYSE:BHVN), a commercial-stage Neuroinnovation company, today announced the companies are initiating a therapeutic discovery and dev

    11/17/2021BHVN
    NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that NURTEC® ODT (rimegepant) was approved by the Kuwait Ministry of Health for the acute treatment of migraine with and without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.

    11/15/2021BHVN
    Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that enrollment is now complete in the verdiperstat arm of the HEALEY ALS Platform Trial. This first-ever platform trial in ALS, sponsored by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), is designed to evaluate the safety and efficacy of multiple drug candidates in people with Amyotrophic Lateral Sclerosis ("ALS"). Verdiperstat was selected as one of the inaugural investigat

    11/11/2021BHVN
    Biohaven Pharma Hldgs Insider Makes $610K Stock Purchase

    John Childs, Insider at Biohaven Pharma Hldgs (NYSE:BHVN), made a large insider buy on November 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Childs purchased 5,000 shares of Biohaven Pharma Hldgs at at prices ranging from $122.75 to $123.30. The total transaction amounted to $614,342. Childs now owns a total of 2,560,801 of Biohaven Pharma Hldgs worth, 314,184,674. Biohaven Pharma Hldgs shares are trad

    11/11/2021BHVN
    The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

    The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

    11/11/2021BHVN
    Traders Should Be Stopped Out of Biohaven Pharmaceutical

    In his first "Executive Decision" segment of Wednesday's Mad Money program, Jim Cramer spoke with Vlad Coric, CEO of Biohaven Pharmaceutical , the biotech. Biohaven just announced a global partnership with Pfizer to bring its migraine treatment, Nurtec ODT, to patients outside the U.S. Coric said in the deal, Biohaven retains the U.S. rights to Nurtec, but leverages Pfizer's global presence to commercialize the drug around the globe.

    11/10/2021BHVN
    Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data

    Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.